SWOG S0727: A randomized phase II trial of combination gemcitabine plus erlotinib plus IMC-A12 (cixutumumab) versus gemcitabine plus erlotinib as first-line treatment in patients (pts) with metastatic pancreatic cancer.

Author(s):

P. A. Philip ◽

B. H. Goldman ◽

R. K. Ramanathan ◽

H. Lenz ◽

A. M. Lowy ◽

...

Keyword(s):

Pancreatic Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

FOLFIRINOX until progression, FOLFIRINOX with maintenance treatment, or sequential treatment with gemcitabine and FOLFIRI.3 for first-line treatment of metastatic pancreatic cancer: A randomized phase II trial (PRODIGE 35-PANOPTIMOX).

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.4000 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 4000-4000 ◽

Cited By ~ 26

Author(s):

Laetitia Dahan ◽

Jean Marc Phelip ◽

Karine Le Malicot ◽

Nicolas Williet ◽

Jérôme Desrame ◽

...

Keyword(s):

Pancreatic Cancer ◽

Phase Ii ◽

Maintenance Treatment ◽

Phase Ii Trial ◽

Sequential Treatment ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

Interim safety analysis of a randomized phase II trial comparing alternate-day oral therapy using S-1 with the standard regimen as a first-line treatment for patients with advanced pancreatic cancer

Journal of Clinical Oncology ◽

10.1200/jco.2015.33.15_suppl.e15267 ◽

2015 ◽

Vol 33 (15_suppl) ◽

pp. e15267-e15267

Author(s):

Hiroaki Yanagimoto ◽

Takuji Okusaka ◽

Hiroshi Ishii ◽

Junji Furuse ◽

Shinichi Ohkawa ◽

...

Keyword(s):

Pancreatic Cancer ◽

Phase Ii ◽

Oral Therapy ◽

Phase Ii Trial ◽

Advanced Pancreatic Cancer ◽

Line Treatment ◽

First Line ◽

Standard Regimen ◽

Randomized Phase Ii ◽

Results of a phase II trial of S-1 as first-line treatment of metastatic pancreatic cancer (CESAR-study group)

Investigational New Drugs ◽

10.1007/s10637-011-9665-x ◽

2011 ◽

Vol 30 (3) ◽

pp. 1184-1192 ◽

Cited By ~ 9

Author(s):

Beate Schultheis ◽

Dirk Strumberg ◽

Lothar Bergmann ◽

Ullrich Graeven ◽

Axel-Rainer Hanauske ◽

...

Keyword(s):

Pancreatic Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Study Group ◽

Line Treatment ◽

First Line ◽

First-line treatment of patients with metastatic pancreatic cancer: results of a Phase II trial with S-1 (CESAR-Study group)

International Journal of Clinical Pharmacology and Therapeutics ◽

10.5414/cpp48470 ◽

2010 ◽

Vol 48 (07) ◽

pp. 470-472 ◽

Author(s):

D. Strumberg ◽

L. Bergmann ◽

U. Graeven ◽

A. Hanauske ◽

R. Lipp ◽

...

Keyword(s):

Pancreatic Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Study Group ◽

Line Treatment ◽

First Line ◽

PACTO: A single center, randomized, phase II study of the combination of nab-paclitaxel and gemcitabine with or without tocilizumab, an IL-6R inhibitor, as first-line treatment in patients with locally advanced or metastatic pancreatic cancer

Annals of Oncology ◽

10.1093/annonc/mdx369.158 ◽

2017 ◽

Vol 28 ◽

pp. v266

Author(s):

I. Chen ◽

J.S. Johansen ◽

T.A. Zimmers ◽

C. Dehlendorff ◽

V. Kirk Parner ◽

...

Keyword(s):

Pancreatic Cancer ◽

Phase Ii ◽

Phase Ii Study ◽

Locally Advanced ◽

Line Treatment ◽

Single Center ◽

First Line ◽

Randomized Phase Ii ◽

Faculty Opinions recommendation of A randomized, phase II trial of standard triweekly compared with dose-dense biweekly capecitabine plus oxaliplatin plus bevacizumab as first-line treatment for metastatic colorectal cancer: XELOX-A-DVS (dense versus standard).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717697918.793457734 ◽

2012 ◽

Author(s):

Hans-Joachim Schmoll

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

Dose Dense ◽

A Randomized Phase II Trial of Pemetrexed plus Irinotecan (ALIRI) versus Leucovorin-Modulated 5-FU plus Irinotecan (FOLFIRI) in First-Line Treatment of Locally Advanced or Metastatic Colorectal Cancer

Oncology ◽

10.1159/000120626 ◽

2007 ◽

Vol 73 (1-2) ◽

pp. 9-20 ◽

Cited By ~ 11

Author(s):

Craig Underhill ◽

David Goldstein ◽

Vera A. Gorbounova ◽

Mikhail Y. Biakhov ◽

Igor S. Bazin ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Locally Advanced ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

Randomized Phase II Trial of CapOX plus Bevacizumab and CapIRI plus Bevacizumab as First‐Line Treatment for Japanese Patients with Metastatic Colorectal Cancer (CCOG‐1201 Study)

The Oncologist ◽

10.1634/theoncologist.2017-0640 ◽

2018 ◽

Vol 23 (8) ◽

pp. 919-927 ◽

Author(s):

Goro Nakayama ◽

Ayako Mitsuma ◽

Yuki Sunagawa ◽

Kiyoshi Ishigure ◽

Hiroyuki Yokoyama ◽

...

Keyword(s):

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Japanese Patients ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity

Annals of Oncology ◽

10.1093/annonc/mdi047 ◽

2005 ◽

Vol 16 (2) ◽

pp. 282-288 ◽

Cited By ~ 83

Author(s):

M.M. Borner ◽

J. Bernhard ◽

D. Dietrich ◽

R. Popescu ◽

M. Wernli ◽

...

Keyword(s):

Quality Of Life ◽

Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

P5-19-03: Albumin-Bound Paclitaxel (ab-pac) Versus Docetaxel for First-Line Treatment of Metastatic Breast Cancer (MBC): Overall Survival and Safety Analysis of a Randomized Phase II Trial.

10.1158/0008-5472.sabcs11-p5-19-03 ◽

2011 ◽

Author(s):

WJ Gradishar ◽

D Krasnojon ◽

S Cheporov ◽

AN Makhson ◽

GM Manikhas ◽

...

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Metastatic Breast Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Metastatic Breast ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽